NEUROGEN CORP
SC 13G, 1999-11-26
PHARMACEUTICAL PREPARATIONS
Previous: WINCANTON CORP, DEF 14C, 1999-11-26
Next: EFFECTIVE MANAGEMENT SYSTEMS INC, DEFS14C, 1999-11-26



<PAGE>

                       SECURITIES AND EXCHANGE COMMISSION
                              WASHINGTON, DC 20549


                                  SCHEDULE 13G
                                 (RULE 13d-102)


             INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT
           TO RULES 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED
                                PURSUANT TO 13d-2
                                (AMENDMENT NO. )(1)


                              NEUROGEN CORPORATION
                              --------------------
                                (Name of Issuer)

                                  COMMON STOCK
                                  ------------
                         (Title of Class of Securities)

                                   64124E 10 6
                                   -----------
                                 (CUSIP Number)



                                NOVEMBER 22, 1999
                                -----------------
             (Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule
is filed:

                  / /      Rule 13d-1(b)
                  /X/      Rule 13d-1(c)
                  / /      Rule 13d-1(d)





- ---------------------------------

1        The remainder of this cover page shall be filled out for a reporting
person's initial filing on this form with respect to the subject class of
securities, and for any subsequent amendment containing information which
would alter disclosures provided in a prior cover page.

         The information required on the remainder of this cover page shall
not be deemed to be "filed" for the purpose of Section 18 of the Securities
Exchange Act of 1934 or otherwise subject to the liabilities of that section
of the Act but shall be subject to all other provisions of the Act (however,
SEE the NOTES).

<PAGE>

- ------------------------------------------------------------------------------
CUSIP NO. 64124E 10 6                  13G      PAGE 2 OF 7 PAGES
- ------------------------------------------------------------------------------

- ------------------------------------------------------------------------------
   1      NAME OF REPORTING PERSON:
                   BIOTECHNOLOGY VALUE FUND, L.P.
          I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY):
- ------------------------------------------------------------------------------
   2      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
                                                              (a) /X/  (b) / /
- ------------------------------------------------------------------------------
   3      SEC USE ONLY

- ------------------------------------------------------------------------------
   4      CITIZENSHIP OR PLACE OF ORGANIZATION
                   DELAWARE
- ------------------------------------------------------------------------------
         NUMBER             5    SOLE VOTING POWER
           OF                             0
         SHARES             --------------------------------------------------
      BENEFICIALLY          6    SHARED VOTING POWER
       OWNED BY                           937,645
         EACH               --------------------------------------------------
       REPORTING            7    SOLE DISPOSITIVE POWER
        PERSON                            0
         WITH               --------------------------------------------------
                            8    SHARED DISPOSITIVE POWER
                                          937,645
- ------------------------------------------------------------------------------
   9      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
                   937,645
- ------------------------------------------------------------------------------
   10     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES
          CERTAIN SHARES*                                                  / /
- ------------------------------------------------------------------------------
   11     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
                   6.4%
- ------------------------------------------------------------------------------
   12     TYPE OF REPORTING PERSON*
                   PN
- ------------------------------------------------------------------------------

                     * SEE INSTRUCTIONS BEFORE FILLING OUT!


<PAGE>

- ------------------------------------------------------------------------------
CUSIP NO. 64124E 10 6                  13G      PAGE 3 OF 7 PAGES
- ------------------------------------------------------------------------------

- ------------------------------------------------------------------------------
   1      NAME OF REPORTING PERSON:
                   BVF PARTNERS, L.P.
          I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY):
- ------------------------------------------------------------------------------
   2      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
                                                              (a) /X/  (b) / /
- ------------------------------------------------------------------------------
   3      SEC USE ONLY

- ------------------------------------------------------------------------------
   4      CITIZENSHIP OR PLACE OF ORGANIZATION
                   DELAWARE
- ------------------------------------------------------------------------------
         NUMBER             5    SOLE VOTING POWER
           OF                             0
         SHARES             --------------------------------------------------
      BENEFICIALLY          6    SHARED VOTING POWER
       OWNED BY                           1,789,006
         EACH               --------------------------------------------------
       REPORTING            7    SOLE DISPOSITIVE POWER
        PERSON                            0
         WITH               --------------------------------------------------
                            8    SHARED DISPOSITIVE POWER
                                          1,789,006
- ------------------------------------------------------------------------------
   9      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
                   1,789,006
- ------------------------------------------------------------------------------
   10     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES
          CERTAIN SHARES*                                                  / /
- ------------------------------------------------------------------------------
   11     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
                   12.1%
- ------------------------------------------------------------------------------
   12     TYPE OF REPORTING PERSON*
                   PN
- ------------------------------------------------------------------------------

                     * SEE INSTRUCTIONS BEFORE FILLING OUT!


<PAGE>

- ------------------------------------------------------------------------------
CUSIP NO. 64124E 10 6                  13G      PAGE 4 OF 7 PAGES
- ------------------------------------------------------------------------------

- ------------------------------------------------------------------------------
   1      NAME OF REPORTING PERSON:
                   BVF INC.
          I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY):
- ------------------------------------------------------------------------------
   2      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
                                                              (a) /X/  (b) / /
- ------------------------------------------------------------------------------
   3      SEC USE ONLY

- ------------------------------------------------------------------------------
   4      CITIZENSHIP OR PLACE OF ORGANIZATION
                   DELAWARE
- ------------------------------------------------------------------------------
         NUMBER             5    SOLE VOTING POWER
           OF                             0
         SHARES             --------------------------------------------------
      BENEFICIALLY          6    SHARED VOTING POWER
       OWNED BY                           1,789,006
         EACH               --------------------------------------------------
       REPORTING            7    SOLE DISPOSITIVE POWER
        PERSON                            0
         WITH               --------------------------------------------------
                            8    SHARED DISPOSITIVE POWER
                                          1,789,006
- ------------------------------------------------------------------------------
   9      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
                   1,789,006
- ------------------------------------------------------------------------------
   10     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES
          CERTAIN SHARES*                                                  / /
- ------------------------------------------------------------------------------
   11     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
                   12.1%
- ------------------------------------------------------------------------------
   12     TYPE OF REPORTING PERSON*
                   IA, CO
- ------------------------------------------------------------------------------

                     * SEE INSTRUCTIONS BEFORE FILLING OUT!


<PAGE>

- ------------------------------------------------------------------------------
CUSIP NO. 64124E 10 6                  13G      PAGE 5 OF 7 PAGES
- ------------------------------------------------------------------------------

ITEM 1(A).        NAME OF ISSUER:

                  Neurogen Corporation

ITEM 1(B).        ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES:

                  35 Northeast Industrial Road
                  Branford, CT  06405

ITEM 2(A).        NAME OF PERSON FILING:

                  This schedule is being filed on behalf of the following
persons*:

                  (i)      Biotechnology Value Fund, L.P. ("BVF")
                  (ii)     BVF Partners, L.P.  ("Partners")
                  (iii)    BVF Inc. ("BVF Inc.")

                  *        Attached as Exhibit A is a copy of an agreement
                           between the Persons filing (as specified hereinabove)
                           that this Schedule 13G is being filed on behalf of
                           each of them.

ITEM 2(B).  ADDRESS OF PRINCIPAL BUSINESS OFFICE:

                  The principal business office of the persons comprising the
group filing this Schedule 13G is located at 227 West Monroe Street, Suite 4800,
Chicago, Illinois 60606.

ITEM 2(C).        CITIZENSHIP:

                  BVF:                          a Delaware limited partnership
                  Partners:                     a Delaware limited partnership
                  BVF Inc.:                     a Delaware corporation

ITEM 2(D).        TITLE OF CLASS OF SECURITIES:

                  The class of securities beneficially owned by the persons
filing this statement is common stock.

ITEM 2(E).        CUSIP NUMBER:

                  64124E 10 6

ITEM 3.           IF THIS STATEMENT IS FILED PURSUANT TO RULE 13D-1(C),
                  CHECK THIS BOX:  /X/


<PAGE>

- ------------------------------------------------------------------------------
CUSIP NO. 64124E 10 6                  13G      PAGE 6 OF 7 PAGES
- ------------------------------------------------------------------------------

ITEM 4.  OWNERSHIP:

                  The information in items 1 and 5 through 11 on the cover pages
(pp.2 - 4) on Schedule 13G is hereby incorporated by reference.

ITEM 5.  OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS:

                  If this statement is being filed to report the fact that as of
the date hereof the reporting person has ceased to be the beneficial owner of
more than five percent of the class of securities check the following. / /

ITEM 6.           OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER
                  PERSON:

                  BVF shares voting and dispositive power over the shares of the
Stock it beneficially owns with Partners. Partners and BVF Inc. share voting and
dispositive power over the shares of the Stock they beneficially own with, in
addition to BVF, certain managed accounts on whose behalf Partners, as
investment manager, purchase shares. None of the managed accounts individually
own more than 5% of the Stock of the Issuer.

ITEM 7.           IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH
                  ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING
                  COMPANY:

                  Not applicable.

ITEM 8.           IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF A GROUP:

                  Not applicable.

ITEM 9.           NOTICE OF DISSOLUTION OF GROUP:

                  Not applicable.

ITEM 10.          CERTIFICATION

                  By signing below I certify that, to the best of my knowledge
and belief, the securities referred to above were not acquired and are not held
for the purpose of or with the effect of changing or influencing the control of
the issuer of the securities and were not acquired and are not held in
connection with or as a participant in any transaction having that purpose or
effect.


<PAGE>

- ------------------------------------------------------------------------------
CUSIP NO. 64124E 10 6                  13G      PAGE 7 OF 7 PAGES
- ------------------------------------------------------------------------------

                  After reasonable inquiry and to the best of my knowledge and
belief, I certify that the information set forth in this statement is true,
complete and correct.

Dated:   November 23, 1999


                  BIOTECHNOLOGY VALUE FUND, L.P.

                  By:      BVF Partners L.P., its general partner

                           By:      BVF Inc., its general partner

                                      By: /s/ Mark N. Lampert
                                         --------------------
                                              Mark N. Lampert
                                              President

                  BVF PARTNERS L.P.

                  By:      BVF Inc., its general partner

                           By: /s/ Mark N. Lampert
                              --------------------
                                   Mark N. Lampert
                                   President

                  BVF INC.


                  By:  /s/ Mark N. Lampert
                      --------------------
                           Mark N. Lampert
                           President



<PAGE>

                                    EXHIBIT A

                        AGREEMENT REGARDING JOINT FILING


         The undersigned, Biotechnology Value Fund, L.P., a Delaware limited
partnership, and BVF Partners L.P., a Delaware limited partnership, and BVF
Inc., a Delaware corporation, hereby agree and acknowledge that the
information required by Schedule 13G, to which this Agreement is attached as
an exhibit, is filed on behalf of each of them. The undersigned further agree
that any amendments or supplements thereto shall also be filed on behalf of
each of them.

Dated: November 23, 1999

                  BIOTECHNOLOGY VALUE FUND, L.P.

                  By:      BVF Partners L.P., its general partner

                           By:      BVF Inc., its general partner

                                      By: /s/ Mark N. Lampert
                                         --------------------
                                              Mark N. Lampert
                                              President

                  BVF PARTNERS L.P.

                  By:      BVF Inc., its general partner

                           By: /s/ Mark N. Lampert
                              --------------------
                                   Mark N. Lampert
                                   President

                  BVF INC.

                  By: /s/ Mark N. Lampert
                     --------------------
                          Mark N. Lampert
                          President



© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission